Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics Study By FTC Aims “To Strike The Right Balance”

This article was originally published in The Pink Sheet Daily

Executive Summary

FTC appears skeptical of generic exclusivity for biologics, but the approval procedure would prove a critical factor.

You may also be interested in...



FTC’s Low Blow On FOBs

FTC concludes that extended brand exclusivity – or any generic exclusivity – is unnecessary for a robust follow-on biologics market.

FTC’s Low Blow On FOBs

FTC concludes that extended brand exclusivity – or any generic exclusivity – is unnecessary for a robust follow-on biologics market.

Teva's Lucky Number Seven: Analysis Supports Shorter Exclusivity For Biologics

Paper by AEI fellow Brill challenges the assumptions in the 16-year estimate from Duke's Grabowski.

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel